ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0492

Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Abstract Number: 0493

Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study
Abstract Number: 0494

The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Abstract Number: 0495

Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Abstract Number: 0496

Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
Abstract Number: 0497

Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Abstract Number: 0498

Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Abstract Number: 0499

Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
Abstract Number: 0500

Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
Abstract Number: 0501

Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
Abstract Number: 0502

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Abstract Number: 0503

18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Abstract Number: 0504

Longitudinal Patterns of Vascular Inflammation in Large-vessel Vasculitis
Abstract Number: 0505

Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Abstract Number: 0506

Transcriptomic Changes Induced by Mavrilimumab versus Tocilizumab in ex-vivo Cultured Arteries from Patients with Giant-cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].